Psychedelics for Substance Use Disorders | Jennifer Mitchell, PhD
This presentation is part of the 2020 State of the Art in Addiction Medicine conference which covers an expansion of treatment into correctional health, hospital consultation services and emergency rooms. It will cover how, despite the pandemic, telehealth can reach those who are isolated. It will address the worrisome trends in fentanyl, methamphetamine, tobacco and benzodiazepines use; legalization of cannabis, treatment updates for youth, cannabis and alcohol in pregnant women; and novel treatments such as non-benzodiazepines for alcohol withdrawal and psychedelics for substance use disorders.
Learners cannot sign up for individual lectures, only for the full 2020 State of the Art in Addiction Medicine. Please contact CSAM (firstname.lastname@example.org) if you have any questions about this online educational offering.
Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice
- Primary care, psychiatry and other specialty field clinicians who want a better understanding of addiction and to improve their care of patients with unhealthy substance use
- Public policy makers, administrators and advocates who want an understanding of the current state of the field of addiction and its grater implications including towards prevention, access to care, integrated systems of care and healthcare technology
- Other healthcare professionals, including psychologists, therapists, nurses, and addiction counselors, who are involved in the treatment of patients with or at risk of substance use
- Explain how ethnicity and socioeconomics impact access to psychedelic treatments.
- Summarize the current research in the field of psychedelic medication development.
- Describe the basic pharmacological and neurological actions of psychedelic medications for substance use disorders.
Jennifer Mitchell, PhD
Dr. Mitchell is an Associate Professor in the Departments of Neurology and Psychiatry at UCSF and is the Deputy ACOS of Research and Development at the San Francisco VA. She also serves on the Research Advisory Panel for the State of California (RAP-C; which is the panel that reviews all scientific protocols that use Schedule 1 and 2 substances) and as a site PI for Phase 2/3 studies evaluating the efficacy of psychedelics for PTSD and MDD.
DISCLOSURE: Dr. Mitchell disclosed that she received grants research support from MAPS and Usona
The California Society of Addiction Medicine (CSAM) is accredited by the California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™, Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing education credit is available for psychologists, therapists, substance use counselors, nurses and physician assistants.
(see additional information on page for parent course)
- 0.75 AMA Category 1
- 0.75 Attendance